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Abstract
Total joint replacement, although considered an excellent surgical
procedure, can be complicated by osteolysis induced by implant
particles and subsequent aseptic loosening of the implant. The
pathogenesis of implant-associated osteolysis includes inflammatory
and osteolytic processes. The sustained chronic inflammatory
response initiated by particulate debris at the implant-bone
interface is manifested by recruitment of a wide array of cell types.
These cells include macrophages, fibroblasts, giant cells,
neutrophils, lymphocytes, and - most importantly - osteoclasts,
which are the principal bone resorbing cells. The ‘cellular
response’ entails secretion of osteoclastogenic and inflammatory
cytokines that favor exacerbated osteoclast activity and enhanced
osteolysis. An appreciation of the complex network that leads to
these cellular and inflammatory responses will form a foundation on
which to develop therapeutic interventions to combat inflammatory
periprosthetic bone loss.
Introduction
Aseptic loosening of joint implants is a disabling condition
that can affect patients 10 to 20 years after joint replacement
surgery (Figure 1). Total joint replacement for end-stage joint
diseases such as osteoarthritis and inflammatory rheumatoid
arthritis is an effective surgical intervention [1]. Unfortunately,
wear debris, primarily generated from the prosthetic joint
articular surface, remains the major factor limiting the survival
of joint implants. Subtle progression of tissue destruction
around the implant imposes a major challenge, because signs
and symptoms may not be clinically apparent until late stages
of failure.
The basis of periprosthetic tissue destruction, the so-called
‘biologic response’ to implant debris, is complex. However,
this response is the outcome of multiple factors, including
physical and biologic components [2,3]. At the core of the
biologic response that leads to osteolysis is activation of the
receptor activator of nuclear factor-κB (RANK)/RANK ligand
(RANKL) axis, which is indicated by expression of RANK,
RANKL, and osteoprotegerin (OPG) in periprosthetic mem-
branes [4,5]. This activation culminates in enhanced
osteoclast recruitment and activity adjacent to bone-implant
interfaces, leading to osteolysis [6,7].
Aseptic loosening and osteolysis: etiology,
pathogenesis, and cellular responses
Wear debris is formed at prosthetic joint articulations,
modular interfaces, and nonarticulating interfaces [1,8].
Although a wide range of particles has been found, the
majority of particles formed are less than 5 µm in diameter
and are randomly shaped. Studies have suggested that the
cellular response to particles may vary with size, shape,
composition, charge, and number of particles [9,10]. Further-
more, it was proposed that particle phagocytosis represents
an important component of the cellular response to implants;
hence, the size of these particles is significant. In this regard,
several reports have estimated that particles ranging from 0.2
to 10 µm in diameter undergo phagocytosis by macrophages
[11]. In vitro studies of macrophage cultures clearly indicated
that smaller polymethylmethacrylate (PMMA) and polyethy-
lene particles (<20 µm) elicited a significantly greater
inflammatory cytokine response, as indicated by increased
release of tumor necrosis factor (TNF), IL-1, IL-6, prosta-
glandin (PG)E2, matrix metalloproteinases, and other factors
[9,12-14]. Although particle phagocytosis has been identified
as a critical component of this biologic response, recent
studies in human macrophages indicate that direct
interactions between particle and cell surface are sufficient to
activate osteoclastogenic signaling pathways [9,15].
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Aseptic loosening can be the result of inadequate initial
fixation, mechanical loss of fixation over time, or biologic loss
of fixation caused by particle-induced osteolysis around the
implant. The causes of particle accumulation vary from
implant interface wear, micromotion occurring in response to
corrosion, oxidative reactions, and minor pathogen
contaminations [2,3]. In general, the initial response is a
localized anti-inflammatory response that is characterized by
formation of fibrous tissue that encapsulates the implant.
Often, synovial fluid and synovial lining membranes are also
formed, and granulomatous tissue is established.
Immunohistochemical studies of these tissues have revealed
an abundance of macrophages, fibroblasts, giant cells,
neutrophils, and lymphocytes [16-18]. However, aseptic
loosening is characterized by poorly vascularized connective
tissue dominated by fibroblasts and macrophages [15].
Subsequently, secretion of proinflammatory factors,
gelatinases, and proteases contributes to periprosthetic
osteolysis and to failure of the joint implant [19]. Perhaps the
most important aspect of the response to particles is its
sustained duration, caused by its resistance to enzymatic
degradation and digestion [20,21]. This characteristic fuels
and continuously builds up the pathologic response, leading
to aggressive osteolysis.
The rate at which particles accumulate is also considered an
important factor in the occurrence of osteolysis. Various
studies found osteolysis to be associated with increased
wear rates [3,12,20,22]. Specifically, areas of increased lysis
were found to contain significantly greater concentrations of
particles (of similar size and shape) as compared with
nonosteolytic regions of the loosened implant at revision
[10,20]. These observations were further supported in vitro
studies in which induction of transcriptional activity and
cytokine release were found to be particle dose dependent.
An effect of particle concentration on secretions by various
types of cells has also been reported [12,21-24]. In primary
human monocytes, release of cytokines, PGE2, and
hexosaminidase was found to depend on size, concentration,
and surface area of particles [12,21-24]. Other studies using
macrophage cell lines found dose-dependent apoptosis of
the cells when they were treated with ceramic and
polyethylene particles [21]. In studies of other cells such as
synovial fibroblasts and chondrocytes, treatment with
increasing doses of cobalt and vanadium was found to have
toxic effects [25].
Clearly, particulate debris load and particle composition are
important factors in the osteolytic process. Therefore,
ongoing investigations into and evaluations of alternative
weight-bearing surfaces are critical if we are to identify
materials that are optimal in terms of minimizing particle
generation over time [15,26]. Ceramics, and use of highly
cross-linked polyethylene and of metal-on-metal articulations
show promise as approaches that may markedly reduce the
production of wear particles.
Biologic and mechanical factors have been incriminated in
the early and late stages of the development of osteolysis
following joint replacement. Inflammatory reactions develop at
early stages as part of the resolution process. These
reactions primarily include increased circulation and elevated
fluid levels in the vicinity of the affected tissue [26,27]. In
addition, apart from massive recruitment of macrophages to
the site of injury, some studies identified recruitment of
lymphocytes, indicating that the immune system may be
involved in this inflammatory response [15,26,28-32].
Perhaps the most complex aspect of this reaction is secretion
of various cytokines and factors by these lymphocytes and
other cells, leading over time to adverse effects [7,33,34].
The cellular and associated inflammatory response is not
restricted to the initial healing process, but rather it appears
to take center stage at progression and in the late stages of
periprosthetic osteolysis.
Several co-factors have been described as facilitating
propagation of inflammatory and eventual osteolytic events.
One major factor relates to poor implant fixation and
subsequent motion. In this regard, ample evidence indicates
that loosening of implants is associated with excessive
motion and physical stress, which result in accelerated
release of particulate debris [24]. This is apparent from the
progressive nature of bone resorption around loose screws
Figure 1
Radiographic appearance of osteolysis. Radiograph of the right hip of
a 68-year-old woman 10 years after undergoing cementless primary
total hip replacement shows inflammatory osteolysis; the periarticular
bone loss is indicated by arrows.Page 3 of 7
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associated with wear debris. In recent years compelling
evidence has been reported indicating that the release of
such debris leads to inflammatory responses that ultimately
result in bone loss. Evidence implicating particulate debris as
a major component in osteolysis is derived from studies
conducted in animal models exposed to particulate debris,
studies with macrophages [35,36] and osteoclasts
conducted in vitro and in vivo, and evaluations of osteolysis
and co-factors in clinically successful and failed total joint
prostheses [21,37-41]. The amounts of particulate debris
around implants in most cases exhibit a fair correlation with
the degree of aseptic loosening, although certain patients
have an exaggerated biologic response to particulate debris.
However, particles have been documented in remote tissues
as well. Factors that contribute to particle distribution include
(but are not limited to) particle number and size, fluid flow,
implant design, and joint space [10,26].
Biology of the osteolytic response
The cellular response is dominated by phagocytes and
macrophages [26,35,42,43]. However, the osteolytic response
includes various cell types, such as osteoclasts, fibroblasts,
and osteoblasts/stromal cells. This is supported by the wide
range of factors that are secreted by various cells, including
cytokines, growth factors, metalloproteinases, prostanoids
and lysosomal enzymes, among others [44,45]. The
mechanisms that underlie induction by particles of cellular
responses and osteolysis are largely unclear and remain
subject to vigorous investigation. It is believed that
recognition of particles relies on phagocytosis of small-sized
particles by macrophages and unidentified cell surface
interactions. The latter interactions may include nonspecific
physical induction of transmembrane proteins or recognition
of cell surface molecules by particles or proteins/factors that
are adherent to the surface. However, the precise nature of
stimulation of cells by particles remains unknown. Further-
more, it is well accepted that host defense cells, which
comprise the core of the inflammatory reaction, recognize
particles and release large quantities of proinflammatory
cytokines and factors [15,26,28-30,32], including TNF, IL-1α
and IL-1β, IL-6, RANKL and PGE2, among others
[34,37,38,42,46-48]. These factors stimulate bone loss by
targeting osteoclasts and their monocytic precursors. In this
regard, RANK/RANKL is the principal axis that regulates the
osteoclastogenic event.
The RANK/RANKL pathway was discovered during the late
1990s and resolved the mystery regarding osteoclast
differentiation from hematopoetic monocyte/macrophage
precursors [7,38]. Osteoclast differentiation is primarily
controlled by the stromal/osteoblast-derived proteins RANKL
(also known as OPG ligand and osteoclast differentiation
factor) and macrophage colony-stimulating factor [49]. A
major breakthrough in our understanding of the regulation of
osteoclastogenesis was achieved with the identification of
OPG, a soluble protein of the TNF receptor family [50] that
binds RANKL and acts as a decoy molecule (for review
[6,7,51]). Several studies have demonstrated that OPG is a
potent inhibitor of bone loss, thus regulating bone density
and mass in mouse and humans. This secreted cytokine was
also shown to be effective in blocking metabolic, pathologic
(including periprosthetic osteolysis), and metastatic bone
loss. A similar approach using soluble extracellular RANK
protein, which is similar to OPG, neutralizes RANKL by
sequestering it in an inactive complex [52]. This approach
was further proven to be effective in vitro and  in vivo by
studies in which Fc-RANK fusion protein was found to block
bone loss pathologies. Also important to regulation of osteo-
clastogenesis and bone loss is that many proinflammatory
and anti-inflammatory cytokines act directly to enhance or
inhibit the RANK/RANKL axis. For example, the effect of TNF
as a stimulator and activator of osteoclastogenesis appears
to be entirely dependent on an active RANK/RANKL pathway
[53]. In this regard, signaling by TNF appears to be
superimposed over pathways initiated by RANKL in
osteoclast precursors. A similar synergistic pattern has been
observed for other pathologic insults such as implant
particles and pathogens. These observations are in discord
with studies indicating that TNF, in the absence of RANK, is
sufficient to induce osteoclastogenesis [54].
Studies conducted in animal models and in vitro cell cultures
have shown that TNF plays a crucial role as a mediator of
particle-induced osteoclastogenic and osteolytic events
[15,42,47]. In this regard, PMMA particles fail to elicit
aggressive osteolysis in TNF receptor null animals or in the
presence of TNF neutralizing agents, for instance various
soluble TNF binding proteins. Likewise, animals that lack
RANK or RANKL resist induction by particles of osteolysis,
which is similar to their protection from arthritic bone erosion
[34,40,47]. This is not unexpected, considering that TNF
family members, especially RANKL, are prerequisites for
osteoclast formation.
Further downstream signaling by wear particles, unsur-
prisingly, overlaps with that of TNF and RANKL. In this regard,
activation of kinases and recruitment of molecules that are
essential for osteoclast differentiation and activation have
been documented [13,15,42,47,55]. Notably, particle-induced
pathways lead to activation of kinases and transcription
factors that are essential for osteoclastogenesis. Among these
are activation of the tyrosine kinase c-src, mitogen-activated
protein kinases, and the nuclear factor-κB (NF-κB) cascade
[7,13,34]. Although activation of these pathways might be
secondary to other events, selective blockade of these
downstream pathways reduces particle transmitted effects.
Potential therapeutic intervention in
inflammatory osteolysis: molecular
approaches to arrest osteoclast activity
The biologic mechanisms of debris-mediated osteolysis are
complex and involve various cell types and inflammatory
Available online http://arthritis-research.com/content/9/S1/S6cytokines of the periprosthetic membrane. Particles inhibit
bone formation by targeting osteoblasts and activating
macrophages and osteoclasts, which leads to significant
periprosthetic bone loss [15,56]. Therefore, in combination
with improvements in implant integration, strategies to target
the cellular components (osteoblasts and osteoclasts) that
contribute to implant failure represent potentially effective
therapeutic interventions. In this regard, it should be noted
that differentiation of bone marrow macrophages (osteoclast
precursors) into mature osteoclasts requires recognition and
binding of the osteoblast, fibroblast, and T cell secreted
factor RANKL by its cognate receptor, RANK, which is
expressed on the surface of osteoclast precursors [6,38,57].
This process is regulated by another factor secreted by
osteoblasts, namely OPG, which acts as a decoy receptor by
binding to RANKL and reducing its bioavailability. On the
other hand, binding of RANKL to RANK prompts induction of
several intracellular pathways by this receptor, leading to
activation of key transcription factors, most notably NF-κB.
It has been reported that the NF-κB family of transcription
factors is central to pathologic responses and is essential for
osteoclast differentiation (for review [7,51]). It consists of
several family members that primarily form heterodimers.
These dimers are found bound to an inhibitory protein
(inhibitor of NF-κB [IκB]) that, in the absence of stimulation,
retains the complex in the cytoplasm. Stimulation by RANKL
or other specific stimuli leads to activation of upstream IκB
kinases (IKKs), which in turn phosphorylate IκB, leading to its
dissociation from the NF-κB complex and eventually to its
degradation by the proteosome system. IκB-liberated NF-κB
then translocates to the nucleus, binds to specific DNA sites,
and induces basal transcription (for review [7,58]).
Knowledge has accumulated of the NF-κB activation
mechanisms that eventually lead to osteoclast formation and,
when induced by factors such as TNF and PMMA particles,
exacerbate osteoclastogenesis and inflammatory responses.
Several approaches that exploit this knowledge have been
designed to perturb this pathway and hence alleviate the
deleterious effects of inflammatory osteolysis. A number of
approaches to osteoclast-based therapy may be considered.
The first involves targeting osteoclast precursor cells, which
are recruited to inflammatory sites by circulating cytokines.
The second entails targeting precursors that are stimulated
by the particle-mediated cellular response to differentiate and
form bone resorbing osteoclasts. The third approach involves
targeting activation mechanisms of mature osteoclasts.
There are various approaches to inhibiting differentiation of
precursor cells to osteoclasts. First and foremost, direct
inhibition of osteoclast differentiation may be achieved by
application of RANKL decoy molecules such as OPG and the
soluble fusion protein RANK-Fc [52,59]. Indeed, studies in
animal models and in vitro osteoclast cultures have identified
significant inhibition of osteoclastogenesis and reduced
hallmarks of osteolysis [16,52]. Other approaches target key
intracellular signal transduction pathways that are essential
for osteoclast differentiation and inflammatory exacerbation of
this process. The transcription factor NF-κB is at the center
of this process, and is essential for both inflammatory and
osteolytic responses; inhibition of NF-κB hinges on disrupting
its translocation to the nuclei, as noted above. Transduction
of a dominant-negative form of the NF-κB inhibitory protein,
IκB, which retains NF-κB in the cytoplasm, was indeed
sufficient to block osteoclast formation and activity
[39,55,60]. Another viable approach is to block activation of
the upstream IKK complex, which is responsible for
phosphorylation of IκB and subsequent activation of NF-κB.
This was possible by introducing a small peptide that perturbs
assembly of the IKK complex and attenuates activation of
NF-κB [61]. More importantly, administration of the dominant-
negative IκB protein or the IKK inhibitory small peptide to
arthritic mice significantly was found to block bone erosion
associated with inflammatory arthritis and particle-induced
osteolysis of calvaria in mice (for review [7]). Because NF-κB
is central to most host immune and inflammatory responses
and induces expression of a large number of genes encoding
proteins that are associated with bone pathology, efforts have
been directed toward identifying specific NF-κB-mediated
genes and their products. Steps in this direction should lead
to the design of a future generation of selective inhibitors that
might be effective in alleviating inflammatory bone loss.
Several genes have been shown to be critical for osteoclast
differentiation. Among these are c-fms, c-fos, RANKL, NF-κB,
c-src, and the proton ATPase [51]. Recent studies have
revealed that proinflammatory cytokines such as TNF act
directly on some of these genes and their products, in
particular c-src and NF-κB, to accelerate osteoclast formation
and cause a potent osteoclastic response (for review [7,62]).
Selective inhibitors of the c-src tyrosine kinase have shown
great promise in halting osteoclast activity, and future studies
should be directed toward testing the effect of such inhibitors
on inflammatory osteolysis [63,64]. Another promising
approach involves the use of bisphosphonates [65]. These
compounds inhibit osteoclast function and induce their
apoptosis. Animal models have been used to study the
efficacy of an oral bisphosphonate in inhibiting bone
resorption mediated by wear debris [26,66,67]. The findings
indicate reduced radiographic periprosthetic radiolucency,
although the levels of PGE2 and IL-1 remained elevated in
tissue cultures from these implants. These studies have served
as the basis for clinical trials using alendronate in patients with
radiographically evident osteolytic lesions. In other studies,
bone loss around implant caused by intra-articular injection of
particles was prevented and treated by alendronate [68-71].
Thus, bisphosphonates may be useful in preventing particle-
induced osteolysis around total joint implants.
Inhibiting recruitment of osteoclast precursor and other cells
to the inflammatory site entails use of anti-inflammatory
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and others. It has been proposed that pharmacologic
intervention targeted at the macrophage may provide the
means to slow the response to wear debris. Indeed, local
cytokine inhibition may reduce inflammation in the peri-
prosthetic tissue, and several biologic mediators have been
identified as useful for clinical application. In particular, the
IL-1 receptor antagonist protein has been reported to reduce
inflammation, and the anti-inflammatory cytokine IL-10
appears able to reduce cell mediated reactions in
inflammation [28,72]. Using particle-stimulated murine air
pouch and calvarial models to evaluate the potential of gene
therapy to treat inflammation induced by orthopedic wear
debris, recent studies showed that retroviral vectors
encoding human IL-1 receptor antagonist, human TNF
receptor, and viral IL-10 led to marked decreases in
inflammation, decreased pouch fluid accumulation, and
reduced macrophage influx [40,48]. In the murine air pouch
study, histologic assessments revealed that pouches trans-
duced with viral IL-10 or IL-1 receptor antagonist exhibited a
40% reduction in inflammatory cell infiltration when
compared with nonviral controls or LacZ transduced mem-
branes. The calvaria study corroborated these findings by
independently demonstrating that gene delivery of viral IL-10
inhibits three processes that are critically involved in peri-
prosthetic osteolysis: proinflammatory cytokine production
induced by wear debris, osteoclastogenesis, and osteolysis.
Anti-inflammatory cytokines secreted by T lymphocytes such
as IFN-γ, IL-4, and IL-10 have also been shown to be effective
in antagonizing the actions of proinflammatory cytokines (for
review [7,40]). These cytokines are being now exploited in
erosive inflammatory responses because they arrest osteo-
clast formation. The finding that activated T-helper-1 cells
(which secrete RANKL and proinflammatory cytokines) and
T-helper-2 cells (which secrete IL-4) are present in the
synovium strongly implicates the immune system as a key
regulator of inflammatory bone disease. Of significance is a
recent finding that IL-4 mRNA was more frequently identified
in nonerosive than in erosive disease (38% versus 15%).
These findings provide indirect evidence that IL-4 has bone
sparing effects in vivo. Additionally, IL-4 adenoviral gene
therapy has been shown to be effective in reducing
inflammation, inhibiting proinflammatory cytokine secretion,
and sparing bone destruction in a model of adjuvant-induced
arthritis [73].
Clarifying the molecular mechanisms that underlie the anti-
osteoclastogenic actions of these anti-inflammatory cytokines
should unveil useful molecular targets. In this regard, recent
progress toward elucidating the anti-osteoclastogenic action
of IL-4 and IFN-γ was reported. Specifically, IL-4 binds to
membrane receptors expressed on the surface of osteoclast
precursors, and activates key transcription factors, most
notably the signal transducer and activator of transcription
(STAT)6. The mechanism responsible entails activation by
IL-4 of Janus kinases, which phosphorylate STAT6, promp-
ting its dimerization and translocation to the nucleus, where it
binds to DNA and regulates target genes [74]. In osteoclasts
and their precursors, STAT6 was found to be crucial for IL-4
inhibition of osteoclastogenesis and inhibits inflammatory
bone erosion. Although the precise mechanism is unknown,
STAT6 is presumed to inhibit NF-κB and mitogen-activated
protein kinase activation and thus inhibits transcription of
genes, including those encoding inflammatory cytokines such
as TNF, IL-6, NF-κB family members, and more [75]. These
observations indicate that STAT6 is a potentially useful target
for anti-erosive drug design.
IFN-γ is another major product of immune cells that potently
inhibits bone resorption (for review [7,58]). Recent reports
illustrated that IFN-γ interferes with the RANK\RANKL signal
transduction in osteoclasts and their precursors. It induces
rapid degradation of TNF receptor associated factor 6, a
RANK adaptor protein. This action results in arrest of RANK
downstream signals, such as NF-κB and c-Jun\Janus kinase
pathways. In another study [76] it was reported that RANKL-
induced secretion of IFN-γ by osteoclast precursors
counterbalances bone resorption by blocking osteoclasto-
genesis in an autoregulatory manner. Although a direct role
for IFNs in particle-induced inflammatory osteolysis has not
yet been established, the possibility that these cytokines will
block the bone loss associated with this disease is worthy of
further investigation.
Conclusion
Aseptic loosening secondary to wear debris mediated
inflammatory osteolysis is a serious health problem and will
have an impact on increasing numbers of patients over the
coming decades. The initial response to particulate debris
includes a subtle inflammatory response, which becomes
more pronounced as osteolysis progresses. The inflammatory
environment provokes a cellular response characterized by
elevated levels of secreted factors such as TNF, RANKL, IL-6,
IL-1, and IL-11. Most of these cytokines affect osteoclast
differentiation and activity directly, and result in enhanced
osteolysis. Clarifying the molecular details of these signaling
cascades and cellular responses represents, and will
continue to represent, an enormous therapeutic challenge.
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